ReviewClinical pharmacokinetics2014
Pharmacokinetics of antidepressants in patients with hepatic impairment.
Review in Clinical pharmacokinetics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Dose Recommendations for Common Drugs in Patients with Liver Cirrhosis: A Systematic Literature Review.Clinical drug investigation · 2023Pooled it
- Effects of Opioids, Benzodiazepines, Gabapentinoids, and Antidepressants on Fracture Risk in Alcohol-Related Cirrhosis.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Evaluation and management of primary sclerosing cholangitis patients awaiting liver transplantation.JHEP reports : innovation in hepatology · 2026Review
- Optimizing antidepressant use in geriatric depression: expert consensus from French societies of geriatrics, old age psychiatry, and clinical pharmacy (SFGG, SF3PA, and SFPC).European psychiatry : the journal of the Association of European Psychiatrists · 2026Article
- Paroxetine attenuated liver fibrosis in liver of bile duct ligated rats: role of P2XNaunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Five-Year Trends in SSRI Consumption: A Precision Medicine Approach to Comparative Analysis Between Serbia and European Countries.Healthcare (Basel, Switzerland) · 2025Article
- Optimizing the diagnosis and treatment of depression in primary care: the emerging role of vortioxetine treatment.Frontiers in psychiatry · 2025Article
- Top Ten Tips Palliative Care Clinicians Should Know About the Physical Manifestations of Psychiatric Illness and Treatment.Journal of palliative medicine · 2024Article
- Antidepressants- and antipsychotics-induced hepatotoxicity.Archives of toxicology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Appropriate use of antidepressant in patients with hepatic impairment requires careful consideration of how the hepatic illness may affect pharmacokinetics. This review aims to analyze pharmacokinetic profile, plasma level variations so as the metabolism of several antidepressants relating to their use in patients with an hepatic impairment. Due to the lack of data regarding hepatic impairment itself, the review is focused mainly on studies investigating pharmacokinetics in hepatic cirrhosis or alcohol-related conditions. More data on reduced hepatic metabolism can be extrapolated by drug studies conducted in elderly populations. Dose adjustment of antidepressants in these patients is important as most of these drugs are predominantly metabolized by the liver and many of them are associated with dose-dependent adverse reactions. As no surrogate parameter is available to predict hepatic metabolism of drugs, dose adjustment according to pharmacokinetic properties of the drugs is proposed. There is a need for a more balanced assessment of the benefits and risks associated with antidepressants use in patients with hepatic impairment, particularly considering pharmacokinetic profile of the drugs to ensure that patients, who would truly benefit from these agents, are not denied appropriate treatment. In conclusion, kinetic studies for centrally acting drugs including antidepressants with predominant hepatic metabolism should be carried out in patients with liver disease to allow precise dose recommendations for enhanced patient safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.